Letermovir for the prophylaxis of cytomegalovirus (CMV) reactivation or disease in adult CMV-seropositive recipients [R+] of an allogeneic haematopoietic stem cell transplant (HSCT).
|NCPE Assessment Process||Complete|
|Rapid review commissioned||12/03/2018|
|Rapid review completed||10/05/2018|
|Rapid Review outcome||A Full pharmacoeconomic assessment is recommended|
|HTA commissioned by the HSE||29/05/2018|
|Pre-submission consultation with Applicant||09/07/2018|
|Submission received from Applicant||02/04/2019|
|Preliminary review sent to Applicant||29/08/2019|
|NCPE assessment re-commenced||27/09/2019|
|Preliminary review # 2 sent to Applicant||25/11/2019|
|NCPE assessment re-commenced||05/12/2019|
|Factual accuracy check sent to Applicant||24/04/2020|
|NCPE assessment re-commenced||01/05/2020|
|NCPE assessment complete||19/05/2020|
|NCPE assessment outcome||The NCPE recommends that letermovir be considered for reimbursement if cost-effectiveness can be improved relative to existing treatments*.|
*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.
The HSE has approved reimbursement following confidential price negotiations March 2021.